Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1,500
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Incidence of Adverse Events (AEs)
Time frame: From Day 1 up to 135 Days after discontinuation of treatment
Incidence of drug related AEs
Time frame: From Day 1 up to 135 Days after discontinuation of treatment
Incidence of AEs leading to Discontinuation
Time frame: From Day 1 up to 135 Days after discontinuation of treatment
Incidence of Serious Adverse Events (SAEs)
Time frame: From signature of Informed Consent up to 135 Days after discontinuation of treatment
Incidence of Select AEs
Time frame: From Day 1 up to 135 Days after discontinuation of treatment
Incidence of Immune-Mediated AEs
Time frame: From Day 1 up to 135 Days after discontinuation of treatment
Incidence of Death
Time frame: From signature of Informed Consent up to 135 Days after discontinuation of treatment
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Local Institution - 0220
Huntsville, Alabama, United States
COMPLETEDUniversity of Arizona College of Medicine
Tucson, Arizona, United States
WITHDRAWNInnovative Clinical Research Institute
Lynwood, California, United States
WITHDRAWNLocal Institution
San Francisco, California, United States
WITHDRAWNLocal Institution - 0099
San Francisco, California, United States
COMPLETEDLocal Institution - 0233
Aurora, Colorado, United States
COMPLETEDLocal Institution - 0095
New Haven, Connecticut, United States
WITHDRAWNLocal Institution - 0088
Washington D.C., District of Columbia, United States
COMPLETEDFlorida Cancer Affiliates
Ocala, Florida, United States
WITHDRAWNLocal Institution
Orlando, Florida, United States
WITHDRAWN...and 389 more locations